AU2017268469C1 - Gene therapy methods for age-related diseases and conditions - Google Patents

Gene therapy methods for age-related diseases and conditions Download PDF

Info

Publication number
AU2017268469C1
AU2017268469C1 AU2017268469A AU2017268469A AU2017268469C1 AU 2017268469 C1 AU2017268469 C1 AU 2017268469C1 AU 2017268469 A AU2017268469 A AU 2017268469A AU 2017268469 A AU2017268469 A AU 2017268469A AU 2017268469 C1 AU2017268469 C1 AU 2017268469C1
Authority
AU
Australia
Prior art keywords
protein
virus
aav
dna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017268469A
Other languages
English (en)
Other versions
AU2017268469A1 (en
AU2017268469B2 (en
Inventor
George M. Church
Noah DAVIDSOHN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of AU2017268469A1 publication Critical patent/AU2017268469A1/en
Publication of AU2017268469B2 publication Critical patent/AU2017268469B2/en
Priority to AU2024219991A priority Critical patent/AU2024219991A1/en
Application granted granted Critical
Publication of AU2017268469C1 publication Critical patent/AU2017268469C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
AU2017268469A 2016-05-20 2017-05-22 Gene therapy methods for age-related diseases and conditions Active AU2017268469C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024219991A AU2024219991A1 (en) 2016-05-20 2024-09-23 Gene therapy methods for age-related diseases and conditions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662339182P 2016-05-20 2016-05-20
US62/339,182 2016-05-20
US201662421665P 2016-11-14 2016-11-14
US62/421,665 2016-11-14
PCT/US2017/033815 WO2017201527A2 (en) 2016-05-20 2017-05-22 Gene therapy methods for age-related diseases and conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219991A Division AU2024219991A1 (en) 2016-05-20 2024-09-23 Gene therapy methods for age-related diseases and conditions

Publications (3)

Publication Number Publication Date
AU2017268469A1 AU2017268469A1 (en) 2019-01-03
AU2017268469B2 AU2017268469B2 (en) 2024-07-25
AU2017268469C1 true AU2017268469C1 (en) 2025-01-02

Family

ID=60326179

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017268469A Active AU2017268469C1 (en) 2016-05-20 2017-05-22 Gene therapy methods for age-related diseases and conditions
AU2024219991A Pending AU2024219991A1 (en) 2016-05-20 2024-09-23 Gene therapy methods for age-related diseases and conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219991A Pending AU2024219991A1 (en) 2016-05-20 2024-09-23 Gene therapy methods for age-related diseases and conditions

Country Status (9)

Country Link
US (2) US12281154B2 (cg-RX-API-DMAC7.html)
EP (1) EP3458585A4 (cg-RX-API-DMAC7.html)
JP (4) JP7632835B2 (cg-RX-API-DMAC7.html)
CN (2) CN117535350A (cg-RX-API-DMAC7.html)
AU (2) AU2017268469C1 (cg-RX-API-DMAC7.html)
BR (1) BR112018073861A2 (cg-RX-API-DMAC7.html)
CA (1) CA3025020A1 (cg-RX-API-DMAC7.html)
MX (2) MX2018014256A (cg-RX-API-DMAC7.html)
WO (1) WO2017201527A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582797A1 (en) * 2017-02-14 2019-12-25 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Naf-1 derived peptides and uses thereof
US11773406B2 (en) * 2017-03-17 2023-10-03 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
AU2018274655B2 (en) * 2017-05-24 2025-01-30 Universitat Autonoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
JP7330517B2 (ja) * 2017-10-20 2023-08-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 異種タンパク質産生のための人工分泌ペプチド
WO2019113061A1 (en) * 2017-12-06 2019-06-13 Klogene Therapeutics, Inc. Compositions and methods for modulating gene expression
SG11202101819QA (en) * 2018-08-30 2021-03-30 Res Inst Nationwide Childrens Hospital Gene therapy for the treatment of galactosemia
JP2022504868A (ja) * 2018-10-18 2022-01-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体
WO2020106351A1 (en) * 2018-11-21 2020-05-28 Klogenix Llc Increasing gene expression
CA3120923A1 (en) * 2018-11-26 2020-06-04 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
AU2020277496A1 (en) 2019-05-23 2021-12-02 Christiana Care Gene Editing Institute, Inc. Gene knockout of variant NRF2 for treatment of cancer
AU2020279829A1 (en) 2019-05-23 2021-12-02 Christiana Care Gene Editing Institute, Inc. Gene knockout of NRF2 for treatment of cancer
EP3983449A1 (en) 2019-06-11 2022-04-20 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated dysregulated plasma kallikrein
US10653731B1 (en) * 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
AU2020346062A1 (en) * 2019-09-13 2022-03-24 Rutgers, The State University Of New Jersey AAV-compatible laminin-linker polymerization proteins
JP7659550B2 (ja) 2019-10-23 2025-04-09 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
AU2020398637A1 (en) * 2019-12-05 2022-06-30 President And Fellows Of Harvard College Methods for treating osteoarthritis
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
EP4142758A4 (en) * 2020-04-28 2025-02-26 President and Fellows of Harvard College High efficiency gene delivery system
CA3182915A1 (en) * 2020-05-13 2021-11-18 Lysogene Compositions and methods for treating gm1 gangliosidosis and other disorders
CN115916985A (zh) * 2020-05-26 2023-04-04 巴塞罗那自治大学 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022115739A2 (en) * 2020-11-30 2022-06-02 Cellular Longevity, Inc. Lnp and liposome compositions for longevity in mammals and methods of using the same
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
KR102590276B1 (ko) * 2021-01-04 2023-10-16 부산대학교 산학협력단 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
JP2022169389A (ja) * 2021-04-27 2022-11-09 国立大学法人北海道大学 イヌＴＧＦ－β受容体ＩＩ
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
US20230018934A1 (en) * 2021-07-16 2023-01-19 Genflow Biosciences Srl Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus
US20240384245A1 (en) * 2021-09-29 2024-11-21 Sirt6 Ltd Method for treating a disease
CN114921480A (zh) * 2022-06-09 2022-08-19 国科宁波生命与健康产业研究院 一种骨细胞Terc基因敲除小鼠模型的构建方法
WO2024064796A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
WO2024064785A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for familial partial lipodystrophy
AU2023347992A1 (en) * 2022-09-21 2025-04-10 Rejuvenate Bio Inc Gene therapy methods for treating mitral valve disease
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
EP4566618A1 (en) * 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140213512A1 (en) * 2011-08-31 2014-07-31 Amgen Inc. Method of Treating or Ameliorating Type 1 Diabetes Using FGF21

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
EP0975771B1 (en) 1997-04-18 2007-07-11 Biogen Idec MA Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
WO2003059396A1 (en) * 2002-01-11 2003-07-24 Sergei Zolotukhin Adiponectin gene therapy
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
WO2006052568A2 (en) * 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
PL1874818T3 (pl) * 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008088401A2 (en) * 2006-09-13 2008-07-24 The Trustees Of Columbia University In The City Of New York Methods for identifying, or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
WO2008157367A1 (en) * 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
EP2455104B1 (en) * 2010-11-19 2013-07-17 Universitätsklinikum Freiburg Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
CN103203027A (zh) * 2011-11-03 2013-07-17 阳明大学 用于治疗和预防老化相关症状的方法和组分
US9422561B2 (en) 2012-01-24 2016-08-23 Bar-Ilan University Treatment of disease by modulation of SIRT6
CN103665166A (zh) * 2012-09-03 2014-03-26 福又达生物科技股份有限公司 犬融合干扰素
US20160120959A1 (en) * 2013-03-14 2016-05-05 The Board Of Regents Of The University Of Oklahoma Use of Klotho Nucleic Acids or Proteins for Treatment of Diabetes and Diabetes-Related Conditions
CA2945325A1 (en) * 2014-04-08 2015-10-15 University Of Southern California Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
CN114853868A (zh) * 2014-10-24 2022-08-05 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CA3033617A1 (en) * 2015-08-11 2017-02-16 Anie Philip Peptidic tgf-beta antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140213512A1 (en) * 2011-08-31 2014-07-31 Amgen Inc. Method of Treating or Ameliorating Type 1 Diabetes Using FGF21

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cui, Xuezhi et al. "Inhibitory effect of a soluble transforming growth factor beta type II receptor on the activation of rat hepatic stellate cells in primary culture." J Hepatology. *
XUEZHI CUI ET AL: "Inhibitory effect of a soluble transforming growth factor [beta] type II receptor on the activation of rat hepatic stellate cells in primary culture", J Hepatol. 2003;39(5):731-737. doi:10.1016/s0168-8278(03)00216-2 *

Also Published As

Publication number Publication date
WO2017201527A2 (en) 2017-11-23
JP2025078652A (ja) 2025-05-20
JP7632835B2 (ja) 2025-02-19
EP3458585A4 (en) 2019-10-30
JP2023078338A (ja) 2023-06-06
MX2022000085A (es) 2022-02-10
CA3025020A1 (en) 2017-11-23
CN109844124A (zh) 2019-06-04
US20190345224A1 (en) 2019-11-14
AU2017268469A1 (en) 2019-01-03
US20250122267A1 (en) 2025-04-17
JP2022033855A (ja) 2022-03-02
AU2017268469B2 (en) 2024-07-25
CN117535350A (zh) 2024-02-09
WO2017201527A3 (en) 2018-02-08
MX2018014256A (es) 2019-08-16
EP3458585A2 (en) 2019-03-27
JP7315284B2 (ja) 2023-07-26
BR112018073861A2 (pt) 2019-02-26
US12281154B2 (en) 2025-04-22
AU2024219991A1 (en) 2024-10-10
JP2019519221A (ja) 2019-07-11
CN109844124B (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
US20250122267A1 (en) Gene Therapy Methods for Age-Related Diseases and Conditions
US11834474B2 (en) AAV's and uses thereof
AU2017227776C1 (en) AAV vectors for treatment of dominant retinitis pigmentosa
IL255747A (en) Administration of Asterase C.1 using adenovirus to treat vascular edema
CN114402075A (zh) 乌谢尔综合征(ush2a)的基因疗法
US20230072954A1 (en) Compositions and methods for circular rna expression
US20240209354A1 (en) MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM
AU2020229886B2 (en) Compositions and methods for treating oculopharyngeal muscular dystrophy (OPMD)
JP2024534362A (ja) 治療用タンパク質を発現させるための肝臓特異的発現カセット、ベクター、及びその使用
CN120129747A (zh) snRNA核酸分子及其应用
CN116323941A (zh) 通过诱导抗肌萎缩蛋白相关蛋白调节元件内的突变增强细胞中抗肌萎缩蛋白相关蛋白表达及其治疗用途

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 SEP 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 23 SEP 2024

FGA Letters patent sealed or granted (standard patent)